Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Drug Therapy
  4. Volume 20, Issue 1
  5. Article
Volume 20, Issue 1
  • ISSN: 1574-8855
  • E-ISSN: 2212-3903

Abstract

Ankylosing spondylitis (AS) is a complex autoimmune and auto-inflammatory disorder characterized by a gradual onset that can progress to spinal ankylosis over time. This chronic condition primarily affects the sacroiliac joints and the spine, often extending its influence to peripheral joints and extra-articular organs, including the eyes AS is associated with significant disability, along with comorbidities such as uveitis and inflammatory bowel disease. Moreover, individuals with AS face an elevated risk of mortality due to cardiovascular disease (CVD). This paper explores the potential benefits of statins, known for their anti-inflammatory and immunomodulatory effects, in mitigating AS-related cardiovascular risk and their therapeutic effects on disease activity.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdth/10.2174/0115748855272102231205111945
2024-01-23
2024-11-26

  • From This Site

    /content/journals/cdth/10.2174/0115748855272102231205111945
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. BrownM.A. KennaT. WordsworthB.P. Genetics of ankylosing spondylitis—insights into pathogenesis.Nat. Rev. Rheumatol.2016122819110.1038/nrrheum.2015.13326439405
     [Google Scholar]
  2. MauroD. ThomasR. GugginoG. LoriesR. BrownM.A. CicciaF. Ankylosing spondylitis: An autoimmune or autoinflammatory disease?Nat. Rev. Rheumatol.202117738740410.1038/s41584‑021‑00625‑y34113018
     [Google Scholar]
  3. BlizzardD.J. PenroseC.T. SheetsC.Z. SeylerT.M. BolognesiM.P. BrownC.R. Ankylosing spondylitis increases perioperative and postoperative complications after total hip arthroplasty.J. Arthroplasty20173282474247910.1016/j.arth.2017.03.04128438449
     [Google Scholar]
  4. HwangM.C. RidleyL. ReveilleJ.D. Ankylosing spondylitis risk factors: A systematic literature review.Clin. Rheumatol.20214083079309310.1007/s10067‑021‑05679‑733754220
     [Google Scholar]
  5. VorugantiA. BownessP. New developments in our understanding of ankylosing spondylitis pathogenesis.Immunology202016129410210.1111/imm.1324232696457
     [Google Scholar]
  6. TavasolianF. LivelyS. PastrelloC. TangM. LimM. PachecoA. QaiyumZ. YauE. BaskurtZ. JurisicaI. KapoorM. InmanR.D. Proteomic and genomic profiling of plasma exosomes from patients with ankylosing spondylitis.Ann. Rheum. Dis.202382111429144310.1136/ard‑2022‑22379137532285
     [Google Scholar]
  7. TavasolianF. InmanR.D. Biology and therapeutic potential of mesenchymal stem cell extracellular vesicles in axial spondyloarthritis.Commun. Biol.20236141310.1038/s42003‑023‑04743‑z37059822
     [Google Scholar]
  8. TavasolianF. PastrelloC. AhmedZ. JurisicaI. InmanR.D. Vesicular traffic-mediated cell-to-cell signaling at the immune synapse in Ankylosing Spondylitis.Front. Immunol.202313110240510.3389/fimmu.2022.110240536741392
     [Google Scholar]
  9. SmithJ.A. Update on ankylosing spondylitis: Current concepts in pathogenesis.Curr. Allergy Asthma Rep.201515148910.1007/s11882‑014‑0489‑625447326
     [Google Scholar]
  10. ZhangL. ZhangY. PanJ. Immunopathogenic mechanisms of rheumatoid arthritis and the use of anti-inflammatory drugs.Intractable Rare Dis. Res.202110315416410.5582/irdr.2021.0102234466337
     [Google Scholar]
  11. BraunJ. BrandtJ. ListingJ. RudwaleitM. SieperJ. Biologic therapies in the spondyloarthritis: New opportunities, new challenges.Curr. Opin. Rheumatol.200315439440710.1097/00002281‑200307000‑0000512819466
     [Google Scholar]
  12. RosenbaumJ.T. Uveitis in spondyloarthritis including psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease.Clin. Rheumatol.2015346999100210.1007/s10067‑015‑2960‑825953065
     [Google Scholar]
  13. CantiniF. NiccoliL. NanniniC. CassaràE. KaloudiO. RizzelloF. GionchettiP. Case-control study on dactylitis, enthesitis, and anterior uveitis in spondyloarthritis associated with inflammatory bowel diseases: Role of coexistent psoriasis.J. Rheumatol.20174491341134610.3899/jrheum.16151828412702
     [Google Scholar]
  14. ManS. JiX. HuL. WangY. MaY. WangL. ZhuJ. HuangF. Characteristics associated with the occurrence and development of acute anterior uveitis, inflammatory bowel disease, and psoriasis in patients with ankylosing spondylitis: Data from the Chinese ankylosing spondylitis prospective imaging cohort.Rheumatol. Ther.20218155557110.1007/s40744‑021‑00293‑033709320
     [Google Scholar]
  15. TsuiF.W.L. LinA. SariI. ZhangZ. TsuiH.W. InmanR.D. Serial Lipocalin 2 and Oncostatin M levels reflect inflammation status and treatment response in axial spondyloarthritis.Arthritis Res. Ther.202123114110.1186/s13075‑021‑02521‑y33990221
     [Google Scholar]
  16. BremanderA. PeterssonI.F. BergmanS. EnglundM. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis.Arthritis Care Res.201163455055610.1002/acr.2040821452267
     [Google Scholar]
  17. ErikssonJ.K. JacobssonL. BengtssonK. AsklingJ. Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis?Ann. Rheum. Dis.201776236437010.1136/annrheumdis‑2016‑20931527283333
     [Google Scholar]
  18. HanC. RobinsonD.W.Jr HackettM.V. ParamoreL.C. FraemanK.H. BalaM.V. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.J. Rheumatol.200633112167217216981296
     [Google Scholar]
  19. SzaboS.M. LevyA.R. RaoS.R. KirbachS.E. LacailleD. CifaldiM. MaksymowychW.P. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: A population‐based study.Arthritis Rheum.201163113294330410.1002/art.3058121834064
     [Google Scholar]
  20. PapagorasC. VoulgariP.V. DrososA.A. Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis.Clin. Exp. Rheumatol.201331461262023406817
     [Google Scholar]
  21. MathieuS SoubrierM Cardiovascular events in ankylosing spondylitis: A 2018 meta-analysis.Annals of the Rheumatic Diseases.20182018213317
     [Google Scholar]
  22. MathieuS. PereiraB. SoubrierM. Cardiovascular events in ankylosing spondylitis: an updated meta-analysis. Seminars in arthritis and rheumatism.Elsevier2015
     [Google Scholar]
  23. WrightK.A. CrowsonC.S. MichetC.J. MattesonE.L. Time trends in incidence, clinical features, and cardiovascular disease in ankylosing spondylitis over three decades: a population-based study.Arthritis Care Res.201567683684110.1002/acr.2251225384671
     [Google Scholar]
  24. PetersM.J. van der Horst-BruinsmaI.E. DijkmansB.A. NurmohamedM.T. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Seminars in arthritis and rheumatism.Elsevier2004
     [Google Scholar]
  25. van der ValkF.M. Bernelot MoensS.J. VerweijS.L. StrangA.C. NederveenA.J. VerberneH.J. NurmohamedM.T. BaetenD.L. StroesE.S.G. Increased arterial wall inflammation in patients with ankylosing spondylitis is reduced by statin therapy.Ann. Rheum. Dis.201675101848185110.1136/annrheumdis‑2016‑20917627084958
     [Google Scholar]
  26. ShenR. QiL. BaiY. NiuL. YinX. YuQ. AB0988 genetic evidence for a bidirectional causal relationship between ankylosing spondylitis and cardiovascular disease.BMJ202310.1136/annrheumdis‑2023‑eular.3525
     [Google Scholar]
  27. KimJ. YoonJ. LeeH. ParkS. KimS. ChoeJ. POS0251 Risk of cardiovascular disease associated with long-term use of non-steroidal anti-inflammatory drugs in ankylosing spondylitis.Annals of the Rheumatic Diseases202310.1136/annrheumdis‑2023‑eular.4205
     [Google Scholar]
  28. MasiA.T. FesslerS.L. BrezkaM.L. WangY. DonohueS.E. Systematic review and meta-analysis of individual serum lipids and analysis of lipid ratios in ankylosing spondylitis and healthy control cohorts: significantly lower mean HDL-cholesterol level in ankylosing spondylitis cohorts.Clin. Exp. Rheumatol.20234191862187436826790
     [Google Scholar]
  29. van der HeijdeD. SieperJ. MaksymowychW.P. DougadosM. Burgos-VargasR. LandewéR. RudwaleitM. BraunJ. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis.Ann. Rheum. Dis.201170690590810.1136/ard.2011.15156321540200
     [Google Scholar]
  30. CzókolyováM. PusztaiA. VéghE. HorváthÁ. SzentpéteriA. HamarA. SzamosiS. HodosiK. DomjánA. SzántóS. KerekesG. SeresI. HarangiM. ParaghG. SzekaneczÉ. SzekaneczZ. SzűcsG. Changes of metabolic biomarker levels upon one-year anti-TNF-α therapy in rheumatoid arthritis and ankylosing spondylitis: Associations with vascular pathophysiology.Biomolecules20211110153510.3390/biom1110153534680168
     [Google Scholar]
  31. LibbyP. RidkerP.M. HanssonG.K. LeducQ. Inflammation in Atherosclerosis.J. Am. Coll. Cardiol.200954232129213810.1016/j.jacc.2009.09.00919942084
     [Google Scholar]
  32. Di MeglioP. Di CesareA. LaggnerU. ChuC.C. NapolitanoL. VillanovaF. TosiI. CaponF. TrembathR.C. PerisK. NestleF.O. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans.PLoS One201162e1716010.1371/journal.pone.001716021364948
     [Google Scholar]
  33. de Armas-RilloL. Quevedo-AbeledoJ.C. de Vera-GonzálezA. González-DelgadoA. García-DopicoJ.A. Jimenez-SosaA. Rodríguez-LozanoC. González-GayM.A. Ferraz-AmaroI. Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activity.Rheumatology20216052296230610.1093/rheumatology/keaa59033295631
     [Google Scholar]
  34. HusseinD.A. FaroukH.M. MobasherS.A. El-AziziN.O. ThabetR.N. EliaR.Z. Atherosclerosis in Egyptian patients with ankylosing spondylitis.Egypt. Rheumatol. Rehabil.20144111710.4103/1110‑161X.128127
     [Google Scholar]
  35. KerekesG. SoltészP. NurmohamedM.T. Gonzalez-GayM.A. TurielM. VéghE. ShoenfeldY. McInnesI. SzekaneczZ. Validated methods for assessment of subclinical atherosclerosis in rheumatology.Nat. Rev. Rheumatol.20128422423410.1038/nrrheum.2012.1622349611
     [Google Scholar]
  36. AkarS. CanG. BinicierO. AksuK. AkinciB. SolmazD. BirlikM. KeserG. AkkocN. OnenF. Quality of life in patients with Takayasu’s arteritis is impaired and comparable with rheumatoid arthritis and ankylosing spondylitis patients.Clin. Rheumatol.200827785986510.1007/s10067‑007‑0813‑918097710
     [Google Scholar]
  37. MauroD. NervianiA. Endothelial dysfunction in systemic lupus erythematosus: Pathogenesis, assessment and therapeutic opportunities.Rev. Recent Clin. Trials201813319219810.2174/157488711366618031409183129542419
     [Google Scholar]
  38. TakagiH. MoriY. UmedaY. FukumotoY. KatoY. ShimokawaK. HiroseH. Abdominal aortic aneurysm with arteritis in ankylosing spondylitis.J. Vasc. Surg.200338361361610.1016/S0741‑5214(03)00231‑312947287
     [Google Scholar]
  39. GanF. FeiY. LiM. WangQ. XuD. HouY. ZengX. ZhangF. The characteristics of patients having ankylosing spondylitis associated with Takayasu’s arteritis.Clin. Rheumatol.201433335535810.1007/s10067‑013‑2444‑724310108
     [Google Scholar]
  40. DehnaviS. SohrabiN. SadeghiM. LansbergP. BanachM. Al-RasadiK. JohnstonT.P. SahebkarA. Statins and autoimmunity: State-of-the-art.Pharmacol. Ther.202021410761410.1016/j.pharmthera.2020.10761432592715
     [Google Scholar]
  41. TothP.P. BanachM. Statins: Then and now.Methodist DeBakey Cardiovasc. J.2019151233110.14797/mdcj‑15‑1‑2331049146
     [Google Scholar]
  42. KoushkiK. ShahbazS.K. MashayekhiK. SadeghiM. ZayeriZ.D. TabaM.Y. BanachM. Al-RasadiK. JohnstonT.P. SahebkarA. Anti-inflammatory action of statins in cardiovascular disease: The role of inflammasome and toll-like receptor pathways.Clin. Rev. Allergy Immunol.202160217519910.1007/s12016‑020‑08791‑932378144
     [Google Scholar]
  43. YebyoH.G. AschmannH.E. KaufmannM. PuhanM.A. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.Am. Heart J.2019210182810.1016/j.ahj.2018.12.00730716508
     [Google Scholar]
  44. BlandA.R. PayneF.M. AshtonJ.C. JamialahmadiT. SahebkarA. The cardioprotective actions of statins in targeting mitochondrial dysfunction associated with myocardial ischaemia-reperfusion injury.Pharmacol. Res.202217510598610.1016/j.phrs.2021.10598634800627
     [Google Scholar]
  45. Sahebkar, A., Chew, G. T., & Watts, G. F. (2014). Recent advances in pharmacotherapy for hypertriglyceridemia.Progress in lipid research, 56,476610.1016/j.plipres.2014.07.002
     [Google Scholar]
  46. FerrettiG. BacchettiT. SahebkarA. Effect of statin therapy on paraoxonase-1 status: A systematic review and meta-analysis of 25 clinical trials.Prog. Lipid Res.201560507310.1016/j.plipres.2015.08.00326416579
     [Google Scholar]
  47. GorabiA.M. KiaieN. PirroM. BianconiV. JamialahmadiT. SahebkarA. Effects of statins on the biological features of mesenchymal stem cells and therapeutic implications.Heart Fail. Rev.20212651259127210.1007/s10741‑020‑09929‑932008148
     [Google Scholar]
  48. Parizadeh, S. M., Azarpazhooh, M. R., Moohebati, M., Nematy, M., Ghayour-Mobarhan, M., Tavallaie, S., Rahsepar, A. A., Amini, M., Sahebkar, A., Mohammadi, M., & Ferns, G. A. (2011). Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial.Lipids46433334010.1007/s11745‑010‑3517‑x
     [Google Scholar]
  49. SerbanC. SahebkarA. UrsoniuS. MikhailidisD.P. RizzoM. LipG.Y.H. Kees HovinghG. KasteleinJ.J.P. KalinowskiL. RyszJ. BanachM. A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations.Sci. Rep.201551990210.1038/srep0990225970700
     [Google Scholar]
  50. SohrevardiS. NasabF. MirjaliliM. BagherniyaM. TaftiA. JarrahzadehM. AzarpazhoohM. SaeidmaneshM. BanachM. JamialahmadiT. SahebkarA. Effect of atorvastatin on delirium status of patients in the intensive care unit: A randomized controlled trial.Arch. Med. Sci.20191751423142810.5114/aoms.2019.8933034522273
     [Google Scholar]
  51. Vahedian-AzimiA MohammadiSM BanachM BeniFH GuestPC Al-RasadiK Improved COVID-19 outcomes following statin therapy: An updated systematic review and meta-analysis.Biomed Research International.20212021
     [Google Scholar]
  52. Sahebkar, A., Serban, C., Mikhailidis, D. P., Undas, A., Lip, G. Y., Muntner, P., Bittner, V., Ray, K. K., Watts, G. F., Hovingh, G. K., Rysz, J., Kastelein, J. J., Banach, M., & Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group (2015). Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials.Thrombosis and haemostasis114354655710.1160/TH14‑11‑0937
     [Google Scholar]
  53. KhanM.A. van der LindenS.M. Ankylosing spondylitis and other spondyloarthropathies.Rheum. Dis. Clin. North Am.199016355157910.1016/S0889‑857X(21)00888‑72217958
     [Google Scholar]
  54. MyasoedovaE. KarmacharyaP. Duarte-GarciaA. DavisJ.M.III MuradM.H. CrowsonC.S. Effect of statin use on the risk of rheumatoid arthritis: a systematic review and meta-analysis. Seminars in arthritis and rheumatism.Elsevier2020
     [Google Scholar]
  55. BahramiA. ParsamaneshN. AtkinS.L. BanachM. SahebkarA. Effect of statins on toll-like receptors: A new insight to pleiotropic effects.Pharmacol. Res.201813523023810.1016/j.phrs.2018.08.01430120976
     [Google Scholar]
  56. KandeloueiT AbbasifardM ImaniD AslaniS RaziB FasihiM Effect of statins on serum level of hs-CRP and CRP in patients with cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials.Mediators Inflamm.20222022873236010.1155/2022/8732360
     [Google Scholar]
  57. SheridanA. Wheeler-JonesC.P.D. GageM.C. The immunomodulatory effects of statins on macrophages.Immuno20222231734310.3390/immuno2020021
     [Google Scholar]
  58. SatnyM. HubacekJ.A. VrablikM. Statins and inflammation.Curr. Atheroscler. Rep.202123128010.1007/s11883‑021‑00977‑634851454
     [Google Scholar]
  59. CowardW.R. MareiA. YangA. Vasa-NicoteraM.M. ChowS.C. Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes.J. Immunol.200617695284529210.4049/jimmunol.176.9.528416621994
     [Google Scholar]
  60. Blanco-ColioL.M. TuñónJ. Martín-VenturaJ.L. EgidoJ. Anti-inflammatory and immunomodulatory effects of statins.Kidney Int.2003631122310.1046/j.1523‑1755.2003.00744.x12472764
     [Google Scholar]
  61. KimK-J KangNE OhYS JangS-E Eupatilin alleviates hyperlipidemia in mice by inhibiting HMG-CoA reductase.Biochemistry Research International.20232023
     [Google Scholar]
  62. NežićL. AmidžićL. ŠkrbićR. GajaninR. MandićD. DumanovićJ. MilovanovićZ. JaćevićV. Amelioration of endotoxin-induced acute lung injury and alveolar epithelial cells apoptosis by simvastatin is associated with up-regulation of Survivin/NF-kB/p65 pathway.Int. J. Mol. Sci.2022235259610.3390/ijms2305259635269738
     [Google Scholar]
  63. KlingbergE. NurkkalaM. CarlstenH. Forsblad-d’EliaH. Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis.J. Rheumatol.20144171349135610.3899/jrheum.13119924931960
     [Google Scholar]
  64. BalasubramanianR. MaideenN.M.P. HMG-CoA reductase inhibitors (Statins) and their drug interactions involving CYP enzymes, P-glycoprotein and OATP transporters-an overview.Curr. Drug Metab.202122532834110.2174/18755453MTEz9MzEj533459228
     [Google Scholar]
  65. MarkowskaA. AntoszczakM. MarkowskaJ. HuczyńskiA. Statins: HMG-CoA reductase inhibitors as potential anticancer agents against malignant neoplasms in women.Pharmaceuticals2020131242210.3390/ph1312042233255609
     [Google Scholar]
  66. GlueckC.J. PanditR. KumarA. WangP. KhayznikovM. HemachrandraK. Statin intolerance because of myalgia, myositis, myopathy, or myonecrosis can in most cases be safely resolved by vitamin d supplementation.N. Am. J. Med. Sci.201573869310.4103/1947‑2714.15391925838999
     [Google Scholar]
  67. NewmanC.B. PreissD. TobertJ.A. JacobsonT.A. PageR.L.II GoldsteinL.B. ChinC. TannockL.R. MillerM. RaghuveerG. DuellP.B. BrintonE.A. PollakA. BraunL.T. WeltyF.K. Statin safety and associated adverse events: A scientific statement from the American Heart Association.Arterioscler. Thromb. Vasc. Biol.2019392e38e8110.1161/ATV.000000000000007330580575
     [Google Scholar]
  68. ArmitageJ. BaigentC. BarnesE. BetteridgeD.J. BlackwellL. BlazingM. Efficacy and safety of statin therapy in older people: A meta-analysis of individual participant data from 28 randomised controlled trials.Lancet20193931017040741510.1016/S0140‑6736(18)31942‑130712900
     [Google Scholar]
  69. XieW. HuangH. XiaoS. YangX. ZhangZ. Effect of statin use on cardiovascular events and all-cause mortality in immune-mediated inflammatory diseases: A systematic review and meta-analysis involving 148,722 participants.Pharmacol. Res.202016010505710.1016/j.phrs.2020.10505732619724
     [Google Scholar]
  70. van DenderenJ.C. PetersM.J. van HalmV.P. van der Horst-BruinsmaI.E. DijkmansB.A. NurmohamedM.T. Statin therapy might be beneficial for patients with ankylosing spondylitis.Ann. Rheum. Dis.200665569569610.1136/ard.2005.04450316219702
     [Google Scholar]
  71. BraunJ. LandewéR. HermannK.G.A. HanJ. YanS. WilliamsonP. van der HeijdeD. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter, randomized, double‐blind, placebo‐controlled magnetic resonance imaging study.Arthritis Rheum.20065451646165210.1002/art.2179016646033
     [Google Scholar]
  72. Van DenderenJ.C. PetersM. van HalmV. van der Horst-BruinsmaI. DijkmansB. NurmohamedM. Statin therapy might be beneficial for treating patients with ankylosing spondylitis.Ann. Rheum. Dis.2005
     [Google Scholar]
  73. BurticăSN. BrucknerIV. GurgheanA. Statin therapy in patients with ankylosing spondylitis.Age3510
     [Google Scholar]
  74. HeslingaS.C. PetersM.J. ter WeeM.M. van der Horst-BruinsmaI.E. van SijlA.M. SmuldersY.M. NurmohamedM.T. Reduction of inflammation drives lipid changes in ankylosing spondylitis.J. Rheumatol.201542101842184510.3899/jrheum.15019326329334
     [Google Scholar]
  75. OzaA. LuN. SchoenfeldS.R. FisherM.C. DubreuilM. RaiS.K. ZhangY. ChoiH.K. Survival benefit of statin use in ankylosing spondylitis: A general population-based cohort study.Ann. Rheum. Dis.201776101737174210.1136/annrheumdis‑2017‑21125328698231
     [Google Scholar]
  76. SembA.G. RollefstadS. CVD prevention and statin therapy in ankylosing spondylitis.Nat. Rev. Rheumatol.201612844144210.1038/nrrheum.2016.10327357255
     [Google Scholar]
  77. SembA.G. KvienT.K. DeMiccoD.A. FayyadR. WunC.C. LaRosaJ.C. BetteridgeJ. PedersenT.R. HolmeI. Effect of intensive lipid‐lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease.Arthritis Rheum.20126492836284610.1002/art.3452422576673
     [Google Scholar]
  78. DauJ. Associations of statin usage with disease activity in ankylosing spondylitis.2018 ACR/ARHP Annual Meeting2018
     [Google Scholar]
  79. MoonJ. LeeS.Y. NaH.S. LeeA.R. ChoK.H. ChoiJ.W. ParkS.H. ChoM.L. Ezetimibe ameliorates clinical symptoms in a mouse model of ankylosing spondylitis associated with suppression of Th17 differentiation.Front. Immunol.20221392253110.3389/fimmu.2022.92253136059546
     [Google Scholar]
  80. van de PeppelI.P. BertoliniA. van DijkT.H. GroenA.K. JonkerJ.W. VerkadeH.J. Efficient reabsorption of transintestinally excreted cholesterol is a strong determinant for cholesterol disposal in mice.J. Lipid Res.20196091562157210.1194/jlr.M09460731324653
     [Google Scholar]
  81. YanY. HeF. LiZ. XuR. LiT. SuJ. LiuX. ZhaoM. WuW. The important role of apolipoprotein A-II in ezetimibe driven reduction of high cholesterol diet-induced atherosclerosis.Atherosclerosis20192809910810.1016/j.atherosclerosis.2018.11.01630500605
     [Google Scholar]
  82. DauJ. WeismanM. LeeM. WardM. BrownM. DiekmanL. SAT0400 Clinical Factors Impacting Statin Usage in A Longitudinal Ankylosing Spondylitis Cohort.BMJ Publishing Group Ltd201610.1136/annrheumdis‑2016‑eular.3225
     [Google Scholar]
  83. SlobodnickA. ShahB. KrasnokutskyS. PillingerM.H. Update on colchicine, 2017.Rheumatology201857Suppl. 1i4i1110.1093/rheumatology/kex45329272515
     [Google Scholar]
  84. WibetoeG. IkdahlE. KvienT.K. RollefstadS. SembA.G. SAT0395 statin treatment in patients with ankylosing spondylitis.BMJ Publishing Group Ltd201610.1136/annrheumdis‑2016‑eular.5534
     [Google Scholar]
  85. GargN. KrishanP. SyngleA. Rosuvastatin improves endothelial dysfunction in ankylosing spondylitis.Clin. Rheumatol.20153461065107110.1007/s10067‑015‑2912‑325771851
     [Google Scholar]
/content/journals/cdth/10.2174/0115748855272102231205111945
Loading
Protective Effect of Statin Therapy in Ankylosing Spondylitis
Curr Drug Ther 20, 1 (2025); https://doi.org/10.2174/0115748855272102231205111945
/content/journals/cdth/10.2174/0115748855272102231205111945
/content/journals/cdth/10.2174/0115748855272102231205111945
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Ankylosing spondylitis; cardiovascular disease; immunomodulatory effects; inflammatory disease; mortality; statins

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test